Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) [Phase 2]

View source ↗

Summary

A Phase 2 trial of epoetin alfa in anemic patients with low- or intermediate-1 risk myelodysplastic syndromes has been withdrawn from development, with dosing r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Syndromes

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Myelodysplastic Syndromes, Anemia | Phase 2 | Status: WITHDRAWN